PDF(Sci-hub)
Abstract：
Metabolic syndrome (MetS) is a global public health problem affecting nearly 25.9% of the world population characterised by a cluster of disorders dominated by abdominal obesity, high blood pressure, high fasting plasma glucose, hypertriacylglycerolaemia and low HDL-cholesterol. In recent years, marine organisms, especially seaweeds, have been highlighted as potential natural sources of bioactive compounds and useful metabolites, with many biological and physiological activities to be used in functional foods or in human nutraceuticals for the management of MetS and related disorders. Of the three groups of seaweeds, brown seaweeds are known to contain more bioactive components than either red and green seaweeds. Among the different brown seaweed species, Ascophyllum nodosum and Fucus vesiculosus have the highest antioxidant values and highest total phenolic content. However, the evidence base relies mainly on cell line and small animal models, with few studies to date involving humans. This review intends to provide an overview of the potential of brown seaweed extracts Ascophyllum nodosum and Fucus vesiculosus for the management and prevention of MetS and related conditions, based on the available evidence obtained from clinical trials.
摘要：
代谢综合征（MetS）是一个全球性的公共卫生问题，影响了世界人口的近25.9％，其特征是以腹部肥胖为主的一系列疾病。高血压,空腹血糖高，高三酰基甘油血症和低HDL-胆固醇。近年来,海洋生物,尤其是海藻,已被强调为生物活性化合物和有用代谢物的潜在天然来源，具有许多生物和生理活性，可用于功能性食品或人类营养品中，以管理MetS和相关疾病。在三组海藻中，已知棕色海藻比红色和绿色海藻含有更多的生物活性成分。在不同的棕色海藻种类中，夜蛾和云杉具有最高的抗氧化值和最高的总酚含量。然而,证据基础主要依赖于细胞系和小动物模型，迄今为止很少有涉及人类的研究。这篇综述旨在概述褐藻提取物夜蛾和岩藻在管理和预防MetS及相关疾病方面的潜力，基于从临床试验中获得的现有证据。
